EGFR and adenocarcinoma: These findings indicate that lineage plasticity is encoded early in tumor evolution, and that the interplay between AT2-cell origin and tumor-suppressor loss dictates whether EGFR-mutant LUAD retains adenocarcinoma identity or shifts toward an SCLC phenotype.